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respond to treatment in the initial 12 weem model cycle. Patients could relapse or 
continue to respond wto treatment in subsequent cycles. Based on pooled efﬁcacy data 
the initial reponse probability for IVIG used in the model was 0.47(95% C.I. 0.36, 
0.58). Based on a published study, the 12 week proability of relaspe used in the model 
was 0.06 (95% C.I. 0.02,0.14). Non-responding IVIG patients were assumed to be 
switched to corticosteroids. Patients on corticosteroids were at risk of a number of 
adverse events (fracture, diabetes, glaucoma, cataract, serious infection) each cycle. 
RESULTS: Over the 5 year time horizon the model estimated the incrmetnal costs and 
QALYs of IVIG treatment compared to corticosteroid treatment to be $105,356 and 
0.188 repsectively. The incremental cost per QALY of IVIG was estaimated to be 
$551,031. The cost per QALY of IVIG was very sensitive to the assumption on fre-
quency and dosing of maintenance IVIG treatment. CONCLUSIONS: Based on 
common willingness to pay thresholds, IVIG might not be perceived as a cost effective 
treatment for CIDP.
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OBJECTIVES: Conduct an economic evaluation comparing treatment costs between 
5% and 10% Intravenous Immunoglobulin (IVIG) preparations. METHODS: A cost-
minimization analysis (CMA) was performed to compare treatment costs between ﬁve 
5% (including one lyophilized product) and one 10% IVIG preparations, as there are 
no differences in outcomes achieved between different IVIG preparations. The CMA 
was done using a societal perspective and cost included both health care costs as well 
as caregiver costs. More speciﬁcally, the following costs were considered in the model: 
drug costs, facility costs, pharmacy and nursing costs and productivity costs. Other 
data included in the model were obtained from the products’ prescribing information. 
One adult patient (65 kg) and one pediatric patient (25 kg) receiving a dose of 0.4 g/kg 
were modeled. RESULTS: Even though equal cost per gram was assumed across all 
the IVIG products considered in the model, total drug cost was higher for one of the 
5% product because of the limited choice in vial sizes for this particular product. Only 
the lyophilized product incurred pharmacy costs for reconstitution ($15.0). Infusion 
time was shortened by 51 minutes with the 10% product (2.0 h compared to the 5% 
products (2.9 h), saving approximately $21.4 per infusion. For the adult patient, 
nursing costs were higher for the 5% products as more vials were required during the 
infusion (4 to 5 vials for 5% vs. 3 for 10%). On average, the use of a 10% preparation 
saved $65.2 per dose for the adult patient and $32.7 per dose for the pediatric patient. 
Assuming a dosing frequency of 3 weeks, yearly savings could range between $522.2 
and $3.072.2 in adults and $486.8 and $831.6 in children. CONCLUSIONS: The 
availability of a 10% IVIG preparation could generate substantial savings compared 
to 5% preparations.
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OBJECTIVES: Thalidomide is an immonumodulatory drug that has been shown in a 
phase III clinical trial to be effective when used in combination with melphalan and 
prednisone (MPT) in patients newly diagnosed with multiple myeloma who are unable 
to undergo stem cell transplant (SCT) or high-dose chemotherapy (HDC). As part of 
an application to the Pharmaceutical Beneﬁts Advisory Committee (PBAC) in Australia 
we assessed whether such use is cost-effective when compared with MP alone, the 
current standard of care. METHODS: Data on the comparative efﬁcacy of MPT versus 
MP alone were sourced from a completed international phase III study. The results 
from that study showed a statistically signiﬁcant difference in median survival of 1.53 
years (p  0.0006) in favour of MPT. We applied a digitising program to the published 
Kaplan-Meier survival curves in order to estimate the mean survival (area under the 
curve) and extrapolate the results to a lifetime horizon. These data were incorporated 
into a cost-effectiveness analysis taking the perspective of the Australian health care 
system. Outcomes were assessed as quality adjusted life years gained (QALYG), based 
on applying published utility values to the extrapolated survival data. The costs of the 
primary drug therapies (MPT or MP), associated medical services, and the treatment 
of thalidomide related adverse events were all included. Costs and beneﬁts were dis-
counted at 5% per annum, and costs were stated in A$ at 2008 prices. RESULTS: 
The modelled analysis estimated an incremental gain in average survival of 1.47 years. 
This translated into 1.14 QALYGs once the utility values were applied. The associated 
average incremental cost was AUS$23,953. The resulting cost per QALYG was 
A$20,998. CONCLUSIONS: This analysis resulted in a positive recommendation 
from the PBAC to fund thalidomide for the treatment of patients newly diagnosed 
with multiple myeloma.
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OBJECTIVES: This study assesses the cost-effectiveness of Intradiscal electrothermal 
therapy (IDET) relative to femoral ring allografts (FRA), a form of spinal fusion, for 
discogenic back pain. Spinal fusion is an established surgical treatment; IDET is less 
invasive and potentially less costly. McKenna (2005) reported an RCT comparing 
FRA and titanium cage (TC). Based on this trial, Freeman (2007) demonstrated the 
relative cost-effectiveness of FRA. The present study used the same FRA cohort for 
evaluating the cost-effectiveness of IDET vs. FRA. METHODS: Patient-level data on 
resource use up to 24 months and SF-36 (measured pre-operatively and at 6, 12, 24 
months) were available for all 37 FRA patients of McKenna (2005) trial. Comparable 
data were collected prospectively on 85 patients treated with IDET at Queen’s Medical 
Centre, Nottingham. Data variables were matched between the two patient groups. 
Utility scores were produced from SF-36 by using Brazier (2004) algorithm. Differen-
tial costs and utilities, together with 95% conﬁdence intervals, were estimated using 
bias corrected and accelerated bootstrapping. RESULTS: There were no signiﬁcant 
differences between the groups in age, gender or SF-36 domain scores, except physical 
function (p  0.004) and mental health (p  0.021), both lower in the FRA group. 
Baseline utility scores were lower in the FRA group (0.48 vs. 0.52, p  0.03).On the 
central assumptions, the expected cost per patient was lower with IDET by £3713 
(95% CI -£2684 to -£4742). The differential QALYs of IDET vs. FRA (adjusted for 
preoperative utilities) were 0.03 (95% CI -0.07 to 0.12). At a willingness-to-pay 
(WTP) threshold of £20,000 per QALY, the net health beneﬁt (NHB) of IDET was 
0.21 and the probability of IDET being cost-effective was 1. If the WTP threshold 
was £30 K/QALY, the NHB was 0.15 (probability cost-effective  0.997). CONCLU-
SIONS: IDET offers a cost-effective alternative to spinal fusion. IDET has the advan-
tage that it is less invasive and can be performed as a day-case procedure.
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OBJECTIVES: . To evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve 
gastrectomy and gastric banding) versus ordinary treatment in health care. METHODS:  
Analysis was done from health care providers’ perspective using a Markov cycle tree 
and a time horizon of ten years. Events during the ﬁrst year, including mortality and 
primary complications resulting in reoperation, were modelled in a decision tree. Then 
the patient cohort moves into a state transition model including four states: alive (no 
reoperation or abdominoplasty), reoperation, abdominoplasty, and death. The param-
eter values were taken from a large representative population survey measuring health-
related quality of life (HRQoL) and health service use, as well as from registers and 
literature. When necessary, expert opinions were used. Different types of sensitivity 
analysis were conducted. RESULTS: . In CUA bariatric surgery dominated strongly 
the ordinary treatment. The mean cost was a31,800 and a44,800 and the mean 
number of QALYs 7.05 and 6.51 for bariatric surgery and ordinary treatment, respec-
tively. Uncertainty around the parameter values was tested comprehensively in sensi-
tivity analyses and the results were robust. CONCLUSIONS: The model takes into 
account all the major events. Strengths of the model include the actual cost data on 
bariatric surgery and inclusion of abdominoplasty, which seems to be neglected in 
previous analyses. Also, a unique set of data on mean health care costs and HRQoL 
for both alternatives was available. The time horizon is rather short and may under-
estimate the effectiveness of bariatric surgery, but it is based on available follow-up 
data.
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OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-
PCA) processes in postoperative pain management in patients in clinical practice that 
has undergone surgery at the Uppsala University Hospital, Sweden. METHODS: 
A model was designed and visualized via swimlane notation. Sub process levels 
were deﬁned as “education”, “purchasing/depreciation/maintenance”, “procure-
ment”, “supply”, “application” and “disposal”. Based on these, data was collected 
by two research methods, interviews and measurement forms including patient and 
staff satisfaction questionnaires. RESULTS: Ten members of hospital personnel with 
different responsibilities were interviewed to deﬁne the roles and activities involved in 
the entire IV-PCA process. Ten different roles were deﬁned with 149 different activi-
ties. The involved roles and the duration of each activity in the sub process levels 
“supply”, “application” and “disposal” were measured from 85 consecutive patients 
with 13 different surgery types. The average duration of IV-PCA use per patient was 
